Selank
Thr-Lys-Pro-Arg-Pro-Gly-Pro; Selank acetate (salt form)
Source type: Human study. Sources checked .
What the cited research examined
A 62-patient study compared Selank with medazepam using anxiety scales and biological measures.
The small active-comparator study does not establish long-term safety, injectable equivalence, or a general dosing schedule.
Reference facts
- Half-life
- Not established for general human use by the cited source.
- Human dose range
- Not provided. This reference does not recommend a human dose.
- Administration interval
- Not established by these sources. A half-life is not a dosing schedule.
- Storage
- Product-specific information required. These sources do not establish a storage specification.
Safety context
FDA highlights aggregation, impurity concerns and insufficient human safety.
Research results and substance listings are not product approvals. The FDA overview distinguishes current Category 2 entries from withdrawn nominations; withdrawal does not establish safety.
Sources and review method
- Small active-comparator clinical study
- Peptide sequence and mechanistic study
- FDA: bulk substances with potential safety risks (includes withdrawn nominations)
These are bounded summaries of the linked sources, not systematic reviews. An unknown field means that these sources do not establish a general-use value. It does not claim that no other literature exists.
The calculator converts values you provide. The planner organizes entries you choose. Neither tool assesses whether a substance or schedule is appropriate.